JP2015509186A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509186A5 JP2015509186A5 JP2014548197A JP2014548197A JP2015509186A5 JP 2015509186 A5 JP2015509186 A5 JP 2015509186A5 JP 2014548197 A JP2014548197 A JP 2014548197A JP 2014548197 A JP2014548197 A JP 2014548197A JP 2015509186 A5 JP2015509186 A5 JP 2015509186A5
- Authority
- JP
- Japan
- Prior art keywords
- risk
- pappa
- disease
- patient
- recurrent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100014582 PAPPA Human genes 0.000 claims 13
- 101710021133 PAPPA Proteins 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 9
- 239000000523 sample Substances 0.000 claims 9
- 230000000306 recurrent Effects 0.000 claims 8
- 230000003902 lesions Effects 0.000 claims 7
- 210000001519 tissues Anatomy 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 230000002062 proliferating Effects 0.000 claims 6
- 210000000481 Breast Anatomy 0.000 claims 5
- 206010006256 Breast hyperplasia Diseases 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000002068 genetic Effects 0.000 claims 3
- 201000011059 lobular neoplasia Diseases 0.000 claims 3
- 230000011987 methylation Effects 0.000 claims 3
- 238000007069 methylation reaction Methods 0.000 claims 3
- 208000010027 Carcinoma, Intraductal, Noninfiltrating Diseases 0.000 claims 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001419 dependent Effects 0.000 claims 2
- 201000007273 ductal carcinoma in situ Diseases 0.000 claims 2
- 230000031864 metaphase Effects 0.000 claims 2
- 230000000394 mitotic Effects 0.000 claims 2
- 230000001105 regulatory Effects 0.000 claims 2
- 208000003393 Mammary Paget's Disease Diseases 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- 206010033364 Paget's disease of nipple Diseases 0.000 claims 1
- 208000002163 Phyllodes Tumor Diseases 0.000 claims 1
- 206010071776 Phyllodes tumour Diseases 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims 1
- 230000001747 exhibiting Effects 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 230000011278 mitosis Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000031877 prophase Effects 0.000 claims 1
Claims (14)
- 患者の増殖性病変が浸潤性乳癌に進行するリスク及び／又は再発性非浸潤性疾患のリスクを判定する方法であって、前記患者から得られた乳房組織サンプル中のＰＡＰＰＡの存在及び／又はレベルを検出することを含み、ＰＡＰＰＡが存在しない又は対照より低いレベルで存在する場合、浸潤癌への進行リスク及び／又は再発性疾患のリスクがある、方法。
- 患者の増殖性病変が浸潤性乳癌に進行するリスク及び／又は再発性非浸潤性疾患のリスクを判定する方法であって、前記患者から得られたサンプル中におけるＰＡＰＰＡ遺伝子又はその制御若しくはプロモーター配列中の機能喪失に関連する遺伝子変化の存在を検出することを含み、遺伝子変化が存在する場合、浸潤癌への進行リスク及び／又は再発性疾患のリスクがある、方法。
- 前記ＰＡＰＰＡ遺伝子又はその制御若しくはプロモーター配列中の機能喪失に関連する遺伝子変化がメチル化である、請求項２に記載の方法。
- 前記ＰＡＰＰＡの存在が、ＰＡＰＰＡ特異的抗体、又はＰＡＰＰＡの遺伝子、ｍＲＮＡ、若しくは特異的ＰＡＰＰＡ変異に対するプローブを用いて同定される、請求項１〜３のいずれか一項に記載の方法。
- 患者の増殖性病変が浸潤性乳癌に進行するリスク及び／又は再発性非浸潤性疾患のリスクを判定する方法であって、前記患者から得られた乳房組織サンプル中の前期又は前中期にある有糸分裂細胞の割合を同定し、予め定められたカットオフ値と比較することを含み、前記前期又は前中期にある細胞の割合が前記カットオフ値より大きい場合、浸潤性乳癌への進行リスク及び／又は再発性疾患のリスクがある、方法。
- 前記カットオフ値が、前記サンプル中の有糸分裂細胞の少なくとも３０％である、請求項５に記載の方法。
- 前記組織サンプル中の細胞の少なくとも５個が有糸分裂中である、請求項５又は６に記載の方法。
- 前記前期又は前中期にある細胞の割合が、免疫検出を用いて決定される、請求項５〜７のいずれか一項に記載の方法。
- 前記免疫検出が、Ｈ３Ｓ１０ｐｈ抗体を用いて行われる、請求項８に記載の方法。
- 前記組織サンプルが、増殖性病変を示す乳房組織である、請求項１〜９のいずれか一項に記載の方法。
- 前記増殖性病変が、乳管上皮内癌（ＤＣＩＳ）、小葉上皮内癌（ＬＣＩＳ）、及び乳首のパジェット病を含む前浸潤性病変、並びに小葉新生物、小葉上皮内新生物、異型小葉過形成（ＡＬＨ）、平坦型上皮異型（ＦＥＡ）、異型乳管過形成（ＡＤＨ）微小浸潤癌、乳管内乳頭新生物、及び葉状腫瘍を含む悪性度の不明な増殖性病変から選択される、請求項１０に記載の方法。
- 請求項５に従属する場合、前記患者から得られた乳房組織サンプル中のＰＡＰＰＡの存在及び／又はレベルを検出することを更に含み、ＰＡＰＰＡが存在しない又は対照より低いレベルで存在する場合、浸潤性乳癌への進行リスク及び／又は再発性疾患のリスクがある、請求項５〜１１のいずれか一項に記載の方法。
- 前記ＰＡＰＰＡの存在が、ＰＡＰＰＡ特異的抗体を用いて同定される、請求項１２に記載の方法。
- 請求項５に従属する場合、前記患者から得られた乳房組織サンプル中のＰＡＰＰＡ遺伝子又はその制御若しくはプロモーター配列のメチル化の存在を検出することを更に含み、メチル化が存在する場合、浸潤性乳癌への進行リスク及び／又は再発性疾患のリスクがある、請求項５〜１３のいずれか一項に記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1121924.3 | 2011-12-20 | ||
| GB201121924A GB201121924D0 (en) | 2011-12-20 | 2011-12-20 | Detection of breast cancer |
| PCT/GB2012/053223 WO2013093489A2 (en) | 2011-12-20 | 2012-12-20 | Detection and treatment of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509186A JP2015509186A (ja) | 2015-03-26 |
| JP2015509186A5 true JP2015509186A5 (ja) | 2016-02-12 |
Family
ID=45572722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548197A Pending JP2015509186A (ja) | 2011-12-20 | 2012-12-20 | 乳癌の検出及び処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140349931A1 (ja) |
| EP (1) | EP2795331A2 (ja) |
| JP (1) | JP2015509186A (ja) |
| AU (1) | AU2012356379A1 (ja) |
| CA (1) | CA2859734A1 (ja) |
| GB (2) | GB201121924D0 (ja) |
| WO (1) | WO2013093489A2 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3013974A1 (en) * | 2013-06-26 | 2016-05-04 | AFG Technologies S.à.r.l | Screening, diagnosis, prognostication and treatment of ovarian cancer |
| GB201418965D0 (ja) * | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| CN104689213A (zh) * | 2015-03-17 | 2015-06-10 | 苏州市天灵中药饮片有限公司 | 一种治疗小叶增生的中药组合物及其制备方法 |
| US10614920B2 (en) * | 2017-02-22 | 2020-04-07 | International Business Machines Corporation | System and method for computing survivorship risk associated with delaying therapy in breast cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2291059B (en) | 1993-03-19 | 1997-09-24 | North Sydney Area Health Serv | Papp-a,its immunodetection and uses |
| US6638727B1 (en) * | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| WO2002018631A2 (de) * | 2000-09-01 | 2002-03-07 | Epigenomics Ag | Diagnose von bestehenden erkrankungen oder der prädisposition für bestimmte erkrankungen |
| AU2003302018A1 (en) | 2002-05-15 | 2004-06-15 | Mayo Foundation For Medical Education And Research | Methods of detecting ovarian neoplasia |
| EP1545709B1 (en) * | 2002-09-03 | 2007-11-14 | The University of Manitoba | Neoadjuvant treatment of breast cancer |
| WO2005035732A2 (en) * | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
| EP1709421B1 (en) * | 2004-01-09 | 2017-08-02 | Children's Medical Center Corporation | Methods for diagnosis and pronosis of cancers of epithelial origin |
| JP5629894B2 (ja) * | 2004-12-07 | 2014-11-26 | 国立大学法人大阪大学 | 甲状腺乳頭癌を診断するための新規のマーカー |
| PL3248600T3 (pl) * | 2005-02-18 | 2020-09-07 | Abraxis Bioscience, Llc | Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona |
| US20060205651A1 (en) * | 2005-02-25 | 2006-09-14 | Royal College Of Surgeons In Ireland | Method of treating cancer |
| US20100003189A1 (en) * | 2006-07-14 | 2010-01-07 | The Regents Of The University Of California | Cancer biomarkers and methods of use thereof |
| KR20090064378A (ko) * | 2006-08-10 | 2009-06-18 | 온코세라피 사이언스 가부시키가이샤 | 유방암 관련 유전자 및 폴리펩티드 |
| ES2700074T3 (es) * | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
| US8030060B2 (en) * | 2007-03-22 | 2011-10-04 | West Virginia University | Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer |
| AU2008287555A1 (en) * | 2007-08-10 | 2009-02-19 | Agency For Science, Technology And Research (A*Star) | VHZ for diagnosis and treatment of cancer |
| WO2009089548A2 (en) * | 2008-01-11 | 2009-07-16 | H. Lee Moffitt Cancer & Research Institute, Inc. | Malignancy-risk signature from histologically normal breast tissue |
| WO2009092806A2 (en) * | 2008-01-25 | 2009-07-30 | Aarhus Universitet | Selective exosite inhibition of papp-a activity against igfbp-4 |
| US20100317533A1 (en) * | 2009-06-05 | 2010-12-16 | British Columbia Cancer Agency Branch | Biomarkers of cancer metastasis |
| FI20095733A0 (fi) * | 2009-06-29 | 2009-06-29 | Hytest Oy | IGFBP-4-fragmenttien määrittäminen diagnostisena menetelmänä |
| KR20110091423A (ko) * | 2010-02-05 | 2011-08-11 | 국립암센터 | 항―ｔｍａｐ／ｃｋａｐ２ 항체를 포함하는 암의 예후 진단용 조성물 |
| RU2012154025A (ru) * | 2010-05-14 | 2014-06-20 | Дженентек, Инк. | Способы лечения |
-
2011
- 2011-12-20 GB GB201121924A patent/GB201121924D0/en not_active Ceased
-
2012
- 2012-12-20 WO PCT/GB2012/053223 patent/WO2013093489A2/en active Application Filing
- 2012-12-20 AU AU2012356379A patent/AU2012356379A1/en not_active Abandoned
- 2012-12-20 EP EP12813943.3A patent/EP2795331A2/en not_active Withdrawn
- 2012-12-20 GB GB1412831.8A patent/GB2513050A/en not_active Withdrawn
- 2012-12-20 CA CA2859734A patent/CA2859734A1/en not_active Abandoned
- 2012-12-20 US US14/366,878 patent/US20140349931A1/en not_active Abandoned
- 2012-12-20 JP JP2014548197A patent/JP2015509186A/ja active Pending
-
2017
- 2017-02-27 US US15/443,749 patent/US20170298438A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | miR-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis | |
| Ying et al. | Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition | |
| Butt et al. | New frontiers for the cytoskeletal protein LASP1 | |
| Hopkins et al. | Oncofetal gene SALL4 in aggressive hepatocellular carcinoma | |
| JP2015509186A5 (ja) | ||
| Fan et al. | Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro | |
| Fawzy et al. | Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer | |
| Katono et al. | Clinicopathological significance of S100A10 expression in lung adenocarcinomas | |
| Li et al. | S100 protein in breast tumor | |
| Shi et al. | Research advances in HMGN5 and cancer | |
| Li et al. | SNHG and UCA1 as prognostic molecular biomarkers in hepatocellular carcinoma: recent research and meta-analysis | |
| Guastafierro et al. | The influence of breast cancer on the distribution of cherry angiomas on the anterior thoracic wall: a case series study | |
| Kwon et al. | HIPK2 Overexpression and Its Prognostic Role in Human Papillomavirus‐Positive Tonsillar Squamous Cell Carcinoma | |
| De Marco et al. | An emerging role for BAG3 in gynaecological malignancies | |
| Mentis et al. | PIWI family proteins as prognostic markers in cancer: a systematic review and meta-analysis | |
| JP2014527397A5 (ja) | ||
| Shi et al. | Cyr61 promotes growth of pancreatic carcinoma via nuclear exclusion of p27 | |
| Cui et al. | Diagnostic and prognostic potential of circulating and tissue BATF2 in nasopharyngeal carcinoma | |
| Saxena et al. | RAN GTPase and osteopontin in pancreatic cancer | |
| Zhang et al. | The role of 14-3-3 proteins in gynecological tumors | |
| Liu et al. | Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma | |
| Fang et al. | The expression of microRNA-340 and cyclin D1 and its relationship with the clinicopathological characteristics and prognosis of lung cancer | |
| Dong et al. | Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma | |
| Yavrouian et al. | Recent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma | |
| Wang et al. | In vivo and in vitro effect of hepatocarcinoma lymph node metastasis by upregulation of Annexin A7 and relevant mechanisms |